Ronald is one of the founders of 3D-PharmXchange. Next to his role as general partner, he holds roles as CDO and similar positions at various emerging biotech companies. He is an advisor for various regional and strategic development programs in the life sciences and involved in the establishment of a number of early start-up companies. He recently led the development of Glybera™ for uniQure, the 1st approved genetherapy product in the western world and holds strategic knowledge in the areas of translational development, orphan drugs, individualized medicines and biomarker-based development. Prior to co-founding 3D-PharmXchange Ronald was COO and CDO at Kinesis Pharma, responsible for business development and multidisciplinary drug development, leading the team project leaders. During this time he held advisory board positions and interim management positions for clients, supporting them in fund raising, drug development and corporate strategy. Prior to that he worked for various companies, including Tibotec where he was, amongst others, Compound Development Leader for Prezista®.
He is a PhD-level clinical pharmacologist and drug delivery expert by training (Leiden University and UC San Francisco) and started his career in this area at Johnson & Johnson, Belgium.